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Abstract
Mycophenolic acid (MPA) is an active metabolite of mycophenolate mofetil, a new immuno-
suppressive drug effective in the treatment of canine autoimmune diseases. The impact of
MPA on immunity is ambiguous and its influence on the canine immune system is unknown.
The aim of the study was to determine markers of changes in stimulated peripheral canine
lymphocytes after treatment with MPA in vitro. Twenty nine healthy dogs were studied. Phe-
notypic and functional analysis of lymphocytes was performed on peripheral blood mononu-
clear cells cultured with mitogens and different MPA concentrations– 1 μM (10−3 mol/m3),
10 μM or 100 μM. Apoptotic cells were detected by Annexin V and 7-aminoactinomycin D
(7-AAD). The expression of antigens (CD3, CD4, CD8, CD21, CD25, forkhead box P3
[FoxP3] and proliferating cell nuclear antigen [PCNA]) was assessed with monoclonal anti-
bodies. The proliferation indices were analyzed in carboxyfluorescein diacetate succinimi-
dyl ester (CFSE)-labeled cells. All analyses were performed using flow cytometry. The
influence of MPA on apoptosis was dependent on the mechanism of cell activation and
MPA concentration. MPA caused a decrease in the expression of lymphocyte surface anti-
gens, CD3, CD8 and CD25. Its impact on the expression of CD4 and CD21 was negligible.
Its negative influence on the expression of FoxP3 was dependent on cell stimulation. MPA
inhibited lymphocyte proliferation. In conclusion, MPA inhibited the activity of stimulated
canine lymphocytes by blocking lymphocyte activation and proliferation. The influence of
MPA on the development of immune tolerance–expansion of Treg cells and lymphocyte
apoptosis–was ambiguous and was dependent on the mechanism of cellular activation.
The concentration that MPA reaches in the blood may lead to inhibition of the functions of
the canine immune system. The applied panel of markers can be used for evaluation of the
effects of immunosuppressive compounds in the dog.
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Introduction
Mycophenolic acid (MPA) is an active metabolite of mycophenolate mofetil (MMF), an immu-
nosuppressive drug which was recently introduced to veterinary medicine. MPA blocks pro-
duction of guanine nucleotides by non-competitive and reversible inhibition of inosine 5'-
monophosphate dehydrogenase activity (IMPDH) [1, 2]. Its primary mechanism of action,
inhibition of proliferation, reveals itself almost exclusively in activated lymphocytes [3, 4]. Lit-
erature data suggest that its effect goes beyond lymphocyte division arrest. Among others, it
has been shown to selectively inhibit cell metabolic activity, decrease surface antigen expression
and cytokine production and block differentiation into effector cells [3–10]. Previous studies
have proven the efficacy of MPA in organ transplantation and autoimmune disease in humans.
The use of MMF for the treatment of autoimmune diseases resistant to routine therapies is
becoming more widespread also in the dog [11]. Its major advantages include lack of serious
adverse side effects and low risk of toxicity [11]. In the veterinary literature there are sugges-
tions of its application in myasthenia [12–14], immune-mediated hemolytic anemia (IMHA)
[15–17], anaplastic anemia [18], immune-mediated thrombocytopenia [19, 20], pemphigus
vulgaris, pemphigus foliaceus [21–23], inflammatory bowel disease (IBD) [24], glomerular dis-
eases including glomerulonephritis [25, 26], immune-mediated arthritis [27] and necrotizing
meningoencephalitis [28].
In humans therapeutic concentrations of MPA after oral administration vary between 1 μM
(10−3 mol/m3) (0.32 mg/L) and 10 μM (3.2 mg/L) [29–32]. These values are similar to the ones
obtained in dogs treated with MMF at a dose between 10 and 20 mg/kg [32, 33]. Administra-
tion of MMF to dogs at a dose of 7.5 mg/kg twice daily led in some animals to an increase in
the maximal concentration of MPA in the blood to values exceeding 62.5 μM (20 mg/l) [32,
33]. Definitive recommendations for MMF dosing protocols are unavailable.
The action of immunosuppressive drugs can be evaluated by measurement of their target
enzymes activity, but monitoring markers of immune system activity, such as, lymphocyte pro-
liferation and apoptosis, or expression of lymphocyte surface antigens, indicates their true
impact on the immune system [34]. Despite the influence of MPA and MMF on the activity of
the immune system of humans and laboratory animals having been previously evaluated in
multiple studies, data on the impact of MPA on immunity are still ambiguous [4, 35–37]. In
the dog pharmacodynamics of MMF were assessed only by the measurement of IMPDH activ-
ity [38]. There are no published data on the influence of MPA on the canine immune system.
Therefore there is a need for preliminary, preclinical studies evaluating its pharmacodynamic
properties and assessing currently used MMF dosing protocols in the dog.
The aim of this study was to evaluate the influence of MPA on canine lymphocytes in vitro.
The effects of MPA, at concentrations which are reached in the blood of treated animals, on
lymphocyte proliferation, apoptosis and the expression of lymphocyte antigens: CD3, CD4,
CD8, CD21, CD25, FoxP3 and PCNA were assessed.
Materials and Methods
Animals and blood samples
Twenty nine healthy, adult dogs, patients of 4 veterinary clinics in Warsaw, Poland, were
included in the study after initial assessment which included anamnesis, physical examination
and hematology. The inclusion criteria were: lack of clinical and laboratory signs of disease, no
history of treatment or vaccination 2 weeks before blood sampling. The median age of the dogs
was 6 years (range 2–10). All dogs were female neutered, 21 were mixed breed and eight were
Labradors.
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Abbreviations: 7-AAD, 7-aminoactinomycin D;
CFSE, carboxyfluorescein diacetate succinimidyl
ester; ConA, concanavalin A; DMSO, dimethyl
sulfoxide; FSC, forward scatter; MFI, median
fluorescence intensity; MPA, mycophenolic acid;
PBMC, peripheral blood mononuclear cells; PCNA,
proliferating cell nuclear antigen; PHA,
phytohemagglutinin; SEM, standard error of the
mean; SSC, side scatter; μM, 10−3 mol/m3.
Peripheral blood samples were taken by cephalic venipuncture after 12 h fasting. Blood was
anticoagulated with dipotassium ethylenediaminetetraacetic acid (K2-EDTA) or sodium hepa-
rin. K2-EDTA blood was used for hematology testing and heparinized samples were utilized
for flow cytometric determination of the influence of MPA on peripheral blood mononuclear
cells (PBMC) in culture. All analyses were performed at the Department of Pathology and Vet-
erinary Diagnostics at the Faculty of Veterinary Medicine, Warsaw University of Life Sciences
(WULS-SGGW), Warsaw, Poland.
Only excess peripheral blood (3 ml) collected for routine diagnostic tests was used for this
study. The study was not subject to the Polish regulations on animal experiments valid at the
time it was conducted as it did not cause any pain, suffering, distress or lasting harm to the ani-
mal and included only routine procedures performed under veterinary license. The study did
not require a local ethics committee approval. The local ethics committee was informed about
the design of the study and waived approval requirements (Local Ethical Committee for Ani-
mal Experiments at WULS-SGGW). The dogs' owners provided written, informed consent
authorizing the use of the excess blood in this study. The dogs were required to fast for routine
blood sampling; fasting was not required specifically for the purpose of this study.
Hematology
Hematological analysis was performed in all dogs as a part of their initial evaluation. Complete
blood count was done using an Abacus hematology analyzer (Diatron, Budapest, Hungary).
Blood smears were examined with a CX21 light microscope (Olympus, Tokyo, Japan) after
May-Grünwald Giemsa staining.
Mycophenolic acid
MPA (M3536, Sigma-Aldrich, Saint Louis, USA) was dissolved in dimethyl sulfoxide (DMSO)
(D2438, Sigma-Aldrich) in order to obtain a 0.1 M stock solution. The solution was then fur-
ther diluted in DMSO and phosphate-buffered saline (PBS) (P4417, Sigma-Aldrich) and added
to the complete culture medium. Cells were cultured in concentrations which MPA reaches in
the plasma of treated patients [32, 33]. Final MPA concentrations were 1 μM, 10 μM or
100 μM. Control samples were cultured in the presence of DMSO–solvent control. The DMSO
concentration remained constant in all the samples at 0.1% (volume/volume). All solutions
were prepared aseptically on the day of the experiment.
Culture of canine PBMC
Briefly, PBMCs were obtained from heparinized blood by density gradient centrifugation using
Histopaque 1077 (10771, Sigma-Aldrich, specific gravity 1.077 g/ml) according to the manu-
facturer’s instruction. After, the PBMCs were harvested from the plasma Histopaque interface,
the cells were washed with RPMI 1640 culture medium with L-glutamine (SH30027, HyClone,
Thermo Fisher Scientific, Waltham, USA), and an antibiotic and antimycotic (penicillin 500 I.
U./ml, streptomycin 50 μg/ml and neomycin 100 μg/ml) (P4083, Sigma-Aldrich) and the
remaining erythrocytes were lysed by incubation with a 0.153 M tris(hydroxymethyl)amino-
methane (TRIS) (T1503, Sigma-Aldrich) buffered 0.016 M ammonium chloride (A9434,
Sigma-Aldrich) solution (pH 7.2) for 10 min on ice. Next, cells were washed with PBS and
stained with a trypan blue dye (T8154, Sigma-Aldrich) to visualize dead cells according to a
protocol described previously [39]. Sample cellularity and cell viability were assessed in a
Thoma cell counting chamber. Samples designated for the determination of the proliferation
indices were supravitally stained with carboxyfluorescein diacetate succinimidyl ester (CFSE)
before culture. Next, all samples were washed three times with complete culture medium
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consisting of RPMI 1640, L-glutamine, 10% fetal bovine serum (FBS) (SV30160, HyClone,
Thermo Fisher Scientific) and an antibiotic and antimycotic. PBMCs were placed in a 96-well
flat-bottom plate (353072, Falcon, BD) at a concentration of 2x105 cells in 200 μl of the culture
medium per well and cultured for 72 h (37°C, 5% CO2) with or without MPA (various concen-
trations) and mitogens– 1 μg/ml concanavalin A (ConA) (C5275, Sigma-Aldrich) or 10 μg/ml
phytohemagglutinin (PHA) (L1668, Sigma-Aldrich). Optimal concentrations of both mito-
gens, causing the strongest proliferation of cultured canine lymphocytes in conditions identical
with the ones used in this study, were determined in a preliminary study (data not shown). Cell
viability was reassessed after culture using trypan blue staining. The cultured cells were then
used to evaluate the influence of MPA on the proliferation and apoptosis of lymphocytes, as
well as antigen expression.
CFSE labeling
Cell proliferation was assessed through dividing cell tracking (DCT) technique utilizing CFSE
staining as described previously [40, 41]. CFSE is a dye which permanently binds to intracellular
proteins. The reduction of its fluorescence in filial generations allows tracking of cell divisions
[40]. Briefly, the 0.5 mMworking solution of CFSE (21888, Sigma-Aldrich) was obtained by
diluting 5 mM stock DMSO solution in 0.1% bovine serum albumin (BSA) (A7906, Sigma-
Aldrich) in PBS. After evaluation of sample cellularity and cell viability 1x107 cells were sus-
pended in 1 ml of 0.1% BSA in PBS and stained in duplicates with CFSE at a final concentration
of 5 μM for 10 min at 37°C in the dark. The process was stopped by adding 5 ml of cold complete
culture medium and 5 min incubation on ice. Next, the samples were used for establishing a cell
culture as described above. After culture, the ConA and PHA-stimulated samples were washed in
a cold PBS solution and used to assess cell apoptosis. The unstimulated samples were suspended
in the 1X Annexin V Binding Buffer (51-66121E, BD) and analyzed on the flow cytometer.
Annexin V:PE and 7-AAD staining
Annexin V:PE Apoptosis Detection Kit I (559763, BD) containing Annexin V conjugated with
phycoerythrin (PE) and 7-aminoactinomycin D (7-AAD) were used to distinguish non-apo-
ptotic cells from cells in early apoptosis and late apoptosis/necrosis [42–44]. The CFSE-stained
cells cultured with mitogens were labeled in duplicates according to the manufacturer’s instruc-
tions. Briefly, after washing in cold PBS solution, the cells were suspended in 100 μl of the 1X
Annexin V Binding Buffer, 2.5 μl of Annexin V:PE and 2.5 μl of 7-AAD were added and the
samples were incubated in the dark for 15 min at room temp. The incubation was stopped by
addition of 100 μl of the 1X Annexin V Binding Buffer. Samples remained on ice until analysis.
Immunofluorescence staining of lymphocyte antigens
CD3 / CD4 / CD8 and CD21. The influence of the MPA on the expression of lymphocyte
surface antigens–CD3, CD4, CD8 and CD21 –was evaluated in the mitogen-stimulated cells
using the following anti-canine mAbs [45–47]: mouse anti-CD3:FITC (clone CA17.2A12), rat
anti-CD4:PE (clone YKIX302.9) and rat anti-CD8α:Alexa Fluor 647 (clone YCATE55.9)–triple
color reagent (TC014, AbD Serotec) or mouse anti-CD21:PE–single color staining (clone
CA2.1D6, MCA1781PE, AbD Serotec) (Table 1). The cultured cells were washed in the cyto-
metric buffer. Next, 30% FBS in PBS was added to the samples to block the non-specific binding
sites and the samples were incubated with the antibodies at room temp for 30 min. in the dark.
Samples were then washed, resuspended in the cytometric buffer and analyzed on the flow
cytometer. Isotype controls were used–mouse IgG1:FITC, rat IgG2a:PE and rat IgG1:Alexa Fluor
647 –antibody mix (TC022, AbD Serotec) or mouse IgG1:PE (MCA928PE, AbD Serotec).
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CD4 / CD25 / foxP3. Tricolor flow cytometry was used to identify the influence of MPA
on the population of ConA and PHA-stimulated regulatory T (Treg) cells and the expression
of CD25 –a late activation marker. Surface antigens were stained using anti-canine mAbs
(Table 1): rat anti-CD4:FITC (clone YKIX302.9, MCA1038F, AbD Serotec), mouse anti-CD25:
eFluor 660 (clone P4A10, 50–0250, eBioscience, San Diego, USA) according to protocol of
staining extracellular antigens described above [48, 49]. Next, forkhead box P3 (FoxP3) expres-
sion was evaluated using a cross-reactive anti-FoxP3:PE antibody as described previously by
Biller et al. using a FoxP3/Transcription Factor Staining Buffer Set (00–5523, eBioscience) [48,
50]. Briefly, the samples were incubated overnight in the 1X Fixation/Permeabilization solution
at 4°C in the dark. The samples were then washed in a 1X Permeabilization Buffer and incu-
bated with the rat anti-FoxP3:PE mAb (clone FJK-16s, 12–5773, eBioscience) cross-reacting
with dog cells at room temp. for 30 min (Table 1). After staining, the samples were washed
again, suspended in the cytometric buffer and analyzed. Samples incubated with corresponding
isotype were used as a negative control: rat IgG2a:FITC (MCA1212F, AbD Serotec), mouse
IgG1:eFluor 660 (50–4714, eBioscience) and rat IgG2a:PE (12–4321, eBioscience).
PCNA. Lymphocyte proliferation was assessed by evaluation of PCNA expression after
permeabilization of the cells with Leucoperm kit (BUF09, AbD Serotec) with methanol modifi-
cation according to the manufacturer’s recommendations. PCNA is an auxiliary protein of the
DNA polymerase δ the concentration of which increases at the end of the G1 phase of the cell
cycle reaching its peak in S phase [51]. Briefly, the cells cultured with MPA and mitogens were
washed with a cytometric buffer– 3% FBS and 0.1% NaN3 (S2002, Sigma-Aldrich) in PBS.
After fixation of the cells by incubation with cold Leucoperm A reagent for 10 min. at 4°C, ice-
cold absolute methanol was added and the cells were incubated for another 10 min. Next, the
samples were washed with PBS and incubated with a cross-reactive murine anti-PCNAmono-
clonal antibody (mAb) (clone PC10, MCA1558F, AbD Serotec, Kidlington, United Kingdom)
[52–55] conjugated with fluorescein isothiocyanate (FITC) (Table 1) and Leucoperm B reagent
at room temp. for 30 min. in the dark. The samples were then washed, suspended in the cyto-
metric buffer and analyzed. Cells incubated with a corresponding isotype control–mouse
IgG2a:FITC (MCA929F, AbD Serotec) were used as a negative control.
Table 1. Characteristics of monoclonal antibodies used in immunofluorescense staining of lymphocyte antigens.
Antibody Clone Isotype Host
species
Antigen used to raise the antibody Fluorochrome Catalogue
number
Supplier Dilution
Anti-CD3 CA17.2A12 IgG1 Mouse Canine afﬁnity enriched TCR/CD3
membrane proteins isolated from
thymocytes and the T cell line CLGL-90
FITC TC014 AbD Serotec,
UK
1:13
Anti-CD4 YKIX302.9 IgG2a Rat Canine ConA activated T-cell blasts PE/FITC TC014/
MCA1038F
AbD Serotec,
UK
1:13
Anti-
CD8α
YCATE55.9 IgG1 Rat Canine CD8 alpha chimeric human
IgG1 Fc fusion protein
Alexa Fluor
647
TC014 AbD Serotec,
UK
1:13
Anti-
CD21
CA2.1D6 IgG1 Mouse Canine CD21 –likely a homologue of
human CD21
PE MCA1781PE AbD Serotec,
UK
1:13
Anti-
CD25
P4A10 IgG1 Mouse Canine CD25, interleukin-2 receptor
alpha chain
eFluor 660 50–0250 eBioscience,
USA
1:20
Anti-
FoxP3
FJK-16s IgG2a Rat Murine FoxP3 protein PE 12–5773 eBioscience,
USA
1:20
Anti-
PCNA
PC10 IgG2a Mouse Rat PCNA made in the protein A
expression vector pR1T2T
FITC MCA1558F AbD Serotec,
UK
1:10
Abbreviations: ConA, concanavilin A; FITC, ﬂuorescein isothiocyanate; PE, phycoerythrin
doi:10.1371/journal.pone.0154429.t001
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Flow cytometric analysis
Cytometrical analysis was performed using a FACSCanto II flow cytometer with an automated
BD High Throughput Sampler (HTS) and FACSDiva 7.0 software (BD). The instrument was
calibrated using BD FACSDiva CS&T Research Beads (655050, BD) and the Cytometer Setup
and Tracking (CS&T) module in the BD FACSDiva software (BD). For multi-color staining
compensation was set using cells single-positive for each color. The analysis was done within 1
h from cell staining. Lymphocytes were gated based on their light scatter properties. 20,000
cells from the lymphocyte gate were analyzed. For the CFSE assay the proliferation indices
were calculated as a ratio of the percentage of cells proliferating after mitogen stimulation to
the percentage of cells proliferating without stimulation. Cell apoptosis was evaluated by deter-
mination of the percentage of Annexin V:PE and 7-AAD positive cells. The expression of lym-
phocyte antigens was assessed through both the percentage of positive cells and the median
fluorescent intensity (MFI) of the positive cells. Gates were set using isotype control antibodies.
Statistical analysis
Results were presented as mean ± standard error of the mean (SEM). Data obtained from lym-
phocytes cultured with MPA and mitogens (ConA or PHA) were compared with controls
(DMSO solvent control) cultured with the corresponding mitogen only. Statistical analysis was
performed using Statistica 10.0 software (StatSoft, Tulsa, USA). The distribution of the data
was assessed using the Shapiro-Wilk test. Skewed data were normalized using logarithmic
transformation. The significance of differences was evaluated using a repeated measure analysis
of variance (ANOVA) and a Tukey’s honestly significant difference (HSD) post-hoc test. Dif-
ferences were considered significant when p<0.05 and highly significantly different when
p<0.01 or p<0.001.
Results
MPA influence on lymphocyte viability and apoptosis
Viability of lymphocytes was assessed using trypan blue exclusion. Before and after culture with
MPA, the viability of lymphocytes was above 95% for all the samples. Because this method can-
not distinguish necrotic vs. apoptotic cells Annexin V/7-AAD staining to assess the percentage of
early apoptotic and late apoptotic/necrotic cells using flow cytometry was performed.
The strategy for gating canine lymphocytes is presented in S1 Fig. The percentage of ConA-
stimulated lymphocytes in early apoptosis after culture with MPA at the highest concentration
(100 μM) was lower in comparison with the control and MPA at concentrations of 1 μM and
10 μM (p<0.05). Whereas, in samples cultured with PHA the percentage was higher in the
concentration of 10 μM in comparison with the control and the concentration of 1 μM
(p<0.05). A lower percentage of lymphocytes in late apoptosis was observed in the cells cul-
tured with ConA and MPA at concentrations of 1 μM or 10 μM in comparison with the control
(p<0.01) (S1 Table, S2 Fig). Differences in the percentage of dead cells between trypan blue
exclusion test and Annexin V/7-AAD staining could have arised from the higher sensitivity of
the latter.
Influence of MPA on the percentage of CD3+, CD4+, CD8+ T and CD21+
B lymphocyte subpopulations
In cells cultured with MPA at all concentrations and ConA or PHA a lower percentage of
CD3+ T lymphocytes (with the exception of the cells cultured with PHA and 1 μMMPA) and
the MFI of the positive cells were observed in comparison with the control (p<0.05, p<0.01 or
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p<0.001, see Fig 1 and S2 Table for details), indicating that MPA action was concentration-
dependent (S3 Fig).
The percentage of CD21+ B lymphocytes was higher in cells cultured with ConA and 1 μM
MPA (p<0.05) and lower in samples cultured with PHA and MPA at concentrations of 10 μM
(p<0.05) and 100 μM (p<0.01) in comparison with controls. Whereas, the impact of MPA on
the MFI of ConA or PHA-stimulated CD21+ B lymphocytes was not observed in comparison
with controls (S3 Table, S3 Fig).
There was no impact of MPA on the percentage of CD4+ T lymphocytes cultured with
MPA and ConA or PHA in comparison with controls. Whereas, a lower MFI of CD4+ T lym-
phocytes was seen after culture with PHA and 100 μMMPA in comparison with the control
(p<0.05) (S4 Table, S3 Fig).
For the influence of MPA on the percentage of CD8+ T lymphocytes, lower percentages of
CD8+ T lymphocytes cultured with ConA and with MPA at concentrations of 1 μM (p<0.01)
and 10 μM (p<0.05) and lymphocytes cultured with PHA and MPA at concentration of 10 μM
(p<0.05) were noted in comparison with controls. The MFI of the CD8+ T lymphocytes cul-
tured with ConA and MPA at all concentration was lower in comparison with the control
(p<0.001). Whereas for the cells stimulated with PHA the MFI was lower in MPA at 10 μM
(p<0.05) and 100 μM (p<0.001) in comparison with the control (Fig 1, S5 Table, S3 Fig).
The ratio of CD4+/CD8+ T lymphocytes cultured with ConA and 1 μMMPA or PHA and
10 μMMPA was higher in comparison with controls (p<0.05) (S6 Table, S3 Fig).
The percentage of CD4+CD8+ T lymphocytes cultured with ConA and MPA at the concen-
tration of 100 μMwas lower in comparison with the control (p<0.05) (S7 Table, S3 Fig).
The influence of MPA on CD4+CD25+ T and CD4+CD25+FoxP3+ T
lymphocyte subpopulations
Considering the influence of MPA on the percentage of CD4+CD25+ and CD4+CD25+FoxP3+ T
lymphocytes, a marked, decrease was observed in cells cultured with ConA andMPA at all con-
centrations in comparison with the control (p<0.05, p<0.01 or p<0.001, see Fig 2 and S8 and S9
Tables for details). The action of MPA was strongest at 10 μM and 100 μM. The percentage of
CD4+CD25+ T lymphocytes cultured with PHA andMPA at 10 μM and 100 μMwas lower in
comparison with the control (p<0.05). Whereas, the percentage of CD4+CD25+FoxP3+ T lym-
phocytes cultured with PHA was not affected by MPA in comparison with the control. MFI of
Fig 1. The percentage andMFI of CD3+ (A) and CD8+ (B) lymphocytes after 72 h culture of PBMC in a 37°C, 5% CO2
environment with mitogens–ConA or PHA and MPA at different concentrations (1 μM, 10 μM, 100 μM) or without MPA (solvent
control– 0.1% DMSO) (n = 7). Mean ± SEM. *p<0.05, **p<0.01, ***p<0.001 in comparison with control. Abbreviations: ConA,
concanavalin A; CFSE, carboxyfluorescein diacetate succinimidyl ester; DMSO, dimethyl sulfoxide; MFI, median fluorescence
intensity; MPA, mycophenolic acid; PBMC, peripheral blood mononuclear cells; PCNA, proliferating cell nuclear antigen; PHA,
phytohemagglutinin; SEM, standard error of the mean; μM, 10−3 mol/m3.
doi:10.1371/journal.pone.0154429.g001
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CD25+ or FoxP3+ lymphocytes cultured with ConA andMPA at all concentrations was lower in
comparison with the control (p<0.01 or p<0.001, see Fig 2 and S10 Table for details). In the case
of PHA stimulation the MFI of CD25+ lymphocytes was lower in cells cultured with MPA at
10 μM and 100 μM in comparison with the control (p<0.05) (S3 Fig).
Influence of MPA on lymphocytes proliferation
Proliferation of lymphocytes treated with MPA was assessed by PCNA expression and CFSE
labeling.
After culture with MPA at all concentrations, both, ConA or PHA-stimulated samples had
a lower percentage of PCNA+ lymphocytes and MFI of PCNA+ lymphocytes in comparison
with controls (p<0.001). The reduction in the percentage of PCNA+ lymphocytes was concen-
tration-dependent in cells stimulated with ConA. In PHA-stimulated cells the percentage was
lowest at 10 μM. Similar changes were observed for the MFI of the lymphocytes stimulated
with ConA or PHA (Fig 3, S11 Table, S4 Fig).
The lymphocyte proliferation indices, assessed by CFSE labeling, were lower after a 3 day
culture with MPA (at all concentrations) and mitogens (ConA or PHA) in comparison with
controls (p<0.001) (Fig 3, S12 Table, S4 Fig). Taken together, these data indicated that MPA
negatively regulates lymphocyte proliferation.
Discussion
The results of this in vitro study showed that MPA, depending on the culture conditions, did
not influence apoptosis or exhibit an anti- or proapoptotic effect. Moreover, MPA caused a
Fig 2. The percentage of CD4+CD25+ (A), CD4+CD25+FoxP3+ (B) lymphocytes and MFI of FoxP3+ or CD25+ lymphocytes
(C) after 72 h culture of PBMC in a 37°C, 5% CO2 environment with mitogens–ConA or PHA and MPA at different concentrations
(1 μM, 10 μM, 100 μM) or without MPA (solvent control– 0.1% DMSO) (n = 7). Mean ± SEM. *p<0.05, **p<0.01, ***p<0.001 in
comparison with control.
doi:10.1371/journal.pone.0154429.g002
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decrease in the expression of lymphocyte surface antigens, such us, CD3, CD8 and CD25.
Whereas, the influence of MPA on CD4 and CD21 expression was minimal. Depending on the
activator used, MPA decreased or did not affect the expression of FoxP3 by lymphocytes.
Finally, MPA inhibited proliferation of canine lymphocytes.
The results of this study indicated that the effect of MPA on lymphocyte apoptosis was
dependent on the mechanism of cell activation and MPA concentration. In ConA-stimulated
lymphocytes antiapoptotic action of MPA was observed. The influence of MPA on apoptosis
of ConA-stimulated lymphocytes has not been previously evaluated. Discrepancies between
our observation and the results of previous studies obtained using different activators might be
explained by different mechanisms of cellular activation used in these studies or interspecies
differences between the human, laboratory animals and the dog [3, 7, 9, 10, 56–62]. On the
other hand, the results obtained on PHA-stimulated lymphocytes were in agreement with
reports suggesting that MPA can show proapoptotic activity [3, 7, 56, 59–61]. As PHA has
been shown to cause cell death on its own; induction of apoptosis might have been a conse-
quence of a synergistic action of MPA and PHA [63]. Lack of a consistent increase in lympho-
cyte apoptosis was also previously reported and could have been explained by the design of our
study [9, 10, 57, 58, 62, 64]. Quéméneur et al. observed that MPA induces cell apoptosis
through S-phase arrest only in lymphocytes which were in the cell cycle prior to drug treatment
[65]. It can be assumed that the low number of activated lymphocytes at the time of MPA treat-
ment and mitogen stimulation could have prevented consequent manifestation of its proapop-
totic activity in this study [65]. The data on the influence of MPA on lymphocyte apoptosis are
still unclear and its proapoptotic action may be revealed only under certain conditions [9, 66].
A lower expression of CD3 and CD8 surface antigens after MPA treatment; measured as
both, the percentage of positive cells and the MFI of antigens on positive cells was also observed
in our study. This finding was in agreement with the reports showing that a longer incubation
with MPA causes a decrease in the expression of surface antigens, including the expression of
human CD3 [67, 68]. As MPA was previously shown to have an identical influence on the pro-
liferation of activated CD4+ T, CD8+ T and CD21+ B lymphocytes [4, 6, 57] the drop in CD3
and CD8 expression was more likely a consequence of decreased production of these mole-
cules. At the same time the synthesis of CD4 and CD21 might have been more resistant to
MPA action.
This study has also indicated that MPA decreases the expression of an activation marker
CD25 which was in agreement with the majority of previous studies performed on mitogen or
antigen-stimulated human or rat lymphocytes [4, 36, 67, 69–72], as well as, many in vivo
Fig 3. The percentage and MFI of PCNA+ lymphocytes (n = 7) (A) and the proliferation index of CFSE-labeled lymphocytes
(n = 8) (B) after 72 h culture of PBMC in a 37°C, 5% CO2 environment with mitogens–ConA or PHA and MPA at different
concentrations (1 μM, 10 μM, 100 μM) or without MPA (solvent control– 0.1% DMSO) Mean ± SEM. ***p<0.001 in comparison
with control.
doi:10.1371/journal.pone.0154429.g003
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studies [36, 68, 71–74]. Our study has confirmed the findings of Thomson et al. and Prémaud
et al. that the decrease in CD25 expression was partial and only partly depended on MPA con-
centration [68, 70]. It was also previously observed that the concentration that leads to com-
plete inhibition of cell proliferation does not cause a full inhibition of the expression of
activation markers, including CD25 [71, 75].
The way in which MPA inhibits the expression of surface antigens has not yet been fully elu-
cidated. The decrease is suggested to be associated with decreased production of proteins due
to a reduction in RNA synthesis and/or decreased protein G activity [76–78] rather than inhi-
bition of protein glycosylation [29, 30, 79–81]. Alternatively, MPA instead of affecting the true
number of molecules on the surface of the cells may have changed their structural conforma-
tion thereby reducing their ability to bind to monoclonal antibodies used in our study [77].
In our study, the percentage of double-positive CD4+CD8+ lymphocytes was lower only in
the highest concentration of MPA in ConA-stimulated cells suggesting that it is not a sensitive
marker of immunosuppression caused by MPA in the dog, which is contrary to previous obser-
vations made by Diaz-Romero et al. in rats after in vitro treatment of whole blood samples with
calcineurin inhibitors [82]. This discrepancy could have been explained by a distinct mecha-
nism of action of these drugs, as well as, species-specific differences (e.g. different roles and
functions of the double-positive CD4+CD8+ cells in dogs and rats and/or higher resistance of
this population of cells to immunosuppressive treatment in the dog).
The results of our study showed that MPA causes a concentration-dependant decrease in
the expression of FoxP3 only in ConA-stimulated cells which was contrary to the majority of
previous studies [9, 83–86] The decrease might have been a consequence of inhibition of
ConA-induced Treg formation and proliferation [87, 88]. Whereas, in agreement with previous
studies, a negative influence of MPA on the Treg population was not observed in PHA-acti-
vated cells [89–91]. The reason why MPA had a different impact on the Treg lymphocyte pop-
ulation depending on the mechanism of cellular activation remains unknown.
Significant inhibition of proliferation of mitogen-stimulated lymphocytes caused by MPA
was detected by both assays used in this study, PCNA expression and CSFE labeling. This
unsurprising finding was in agreement with multiple previous in vitro and in vivo studies per-
formed in various settings in humans and laboratory animals [29, 30, 69, 71, 92–94]. As
shown, lymphocyte proliferation was blocked by MPA at the lowest concentration used in this
study in concordance with the previous findings of Allison and Eugui, who observed an inhibi-
tion of lymphocyte proliferation in nanomolar concentrations of MPA [95]. We observed a
partially concentration-dependent decrease in proliferation only through the drop in PCNA
expression which was in agreement with previous reports and suggested that the expression of
PCNA may be a more sensitive marker of lymphocyte proliferation in the dog than the CFSE
assay [29, 30, 71, 79, 96, 97].
The results of this study have shown that MPA at concentrations achieved in the blood of
treated patients inhibits the activity of lymphocytes. Cell function significantly decreased at
1 μM and 10 μM. Although, the potency of the drug evaluated through a decrease in CD25 and
PCNA expression was highest at 100 μM an increase in the MMF dose is not recommended
due to an increased risk of adverse effects on the gastrointestinal tract which could lead to dis-
continuation of the therapy. In vivo the clinical effect of MPA treatment would likely be a sum
of all the events caused by various MPA concentrations used in our study.
To the authors’ knowledge this is the first report evaluating the influence of MPA on canine
lymphocytes. The mechanism of MMF action in the dog was previously evaluated only through
IMPDH activity which does not reflect the drug’s impact on the activity of lymphocytes [34,
38]. Many MPA properties (e.g. inhibition of lymphocyte proliferation) were well studied in
human and laboratory animals [4, 35–37]. At the same time many aspects of MPA’s action,
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despite numerous studies in these species, still remain unclear. Our study contributes to the
clarification of these vague aspects of MPA action. Not infrequently responses to drugs can be
very different between species, e.g. dogs and cats. Increased knowledge of the influence of MPA
on canine immunity can be applied in veterinary pharmacotherapy and clinical immunology
and is needed before the use of MMF in the dog becomes more widespread. Information
regarding effects of various concentrations of MPA on canine lymphocytes was necessary for
precise assessment of the effects of MMF treatment and evaluation of currently used MMF dos-
ing protocols. Our findings will likely prove useful in future optimization of MMF dosing,
allowing concurrent development of immune tolerance and minimalization of the risk of devel-
oping adverse effects of the drug, thus enabling maintenance of homeostasis in the immune
system of the treated dogs. This is particularly important considering that the necessity of mon-
itoring MMF treatment in dogs was previously suggested due to high interindividual variability
of its pharmacokinetic properties [32, 98]. The results of this study may also play a significant
role in planning of future in vitro and in vivo studies (including the selection of markers and
activators) on the influence of MPA and other immunosuppressive drugs on the immune sys-
tem of the dog. Our study is also a first report which has proven that flow cytometric assess-
ment of PCNA expression is possible in the dog and should be considered a useful marker of
lymphocyte proliferation in this species.
Despite, the novel and interesting findings, our study has some limitations. The fact that the
study was conducted in vitro on PBMC is one of its drawbacks. It is generally considered that
pharmacodynamic studies using whole blood culture are superior over studies on PBMC as
they mimic to a greater extent in vivo conditions [35, 99, 100]. As information on the possibil-
ity of application of CFSE labeling in whole blood assays is lacking the use of PMBC allowed
standardization of culture conditions in all tests in this study and simultaneous evaluation of
lymphocyte proliferation by 2 different methods. At the same time an in vitro model using
samples from healthy animals is superior to studies on animals with a particular autoimmune
disease or tissues obtained from them and reflects the effect of the drug on immune cells which
is unbiased by multiple confounding factors present in vivo. Accordingly, any studies on phar-
macokinetics/pharmacodynamics (e.g. for antimicrobial drugs), toxicology, bioequivalence
and tolerance studies must be provided on healthy animals [101–104]. The degree of variability
in the expression of canine lymphocyte antigens (e.g. in the control) was similar to the one
observed previously and was not unexpected given that the study included client-owned dogs,
not research colony animals which have a more limited genetic pool [105].
The assessment of immunosuppression in vitro is routinely performed on mitogen-stimulated
cells which better reflects the activation of the immune system in patients with immune-mediated
diseases. At the same time mitogen stimulation can be considered a confounding factor which
can, for instance, alter the expression of canine lymphocyte antigens [106]. Inclusion of an unsti-
mulated control, both, after and without MPA treatment, could have been helpful in elucidating
the more equivocal results of this study. Lack of the above is another limitation of this study.
Although the mechanism of action of both mitogens used in this study, ConA and PHA, is quite
similar, they produce significantly different effects in canine lymphocytes. ConA causes a higher
expression of FoxP3 and CD25 than PHA. Whereas, PHA increases the percentage of apoptotic
cells and the expression of CD4 and CD8 in comparison with ConA (data not shown). The use
of both mitogens in this study allowed a more comprehensive evaluation of the lymphocytes.
The impact of MPA on cytokines, molecules playing a crucial role in stimulation and modu-
lation of the immune response, was not evaluated which is also a limitation of this study [107].
The type and amount of cytokine production allows assessment of the immune system activity
and immune response direction. A shift in the pattern of cytokine production may change the
net immune response even when a deviation in the absolute or relative cell number does not
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occur. As cytokines may have different, frequently totally opposite, effects on immunity
depending on the cells from which they originate, methods which simultaneously measure
cytokine synthesis and assess the lineage of the producing cells are preferred, e.g. intracellular
cytokine staining and subsequent multiparametric flow cytometric analysis [34, 108–110].
Despite reports suggesting that MPA preferentially blocks the Th2 cytokine response in
humans [111–113] the exact effect of MPA on Th1/Th2 cytokine balance (cell-mediated versus
humoral immunity) still needs to be elucidated [114, 115]. Future studies should evaluate the
influence of MPA on Th1 cytokines (e.g. interferon-γ [IFN-γ] and interleukin-2 [IL-2]), Th2
cytokines (e.g. IL-4), and anti-inflammatory cytokines (e.g. IL-10 and transforming growth fac-
tor-β [TGF-β]) in the dog.
Further studies should also focus on the influence of MPA on the expression of activation
markers other than CD25, including early activation markers, e.g., CD69 and CD71. Also
assessment of the impact of MPA on NK and Th17 lymphocyte populations and Th17/Treg
ratio are important in terms of evaluation of MPA pharmacodynamics in the dog.
Accurate assessment of lymphocyte activity in the dog is limited in comparison with
humans and laboratory animals due to a small number of anti-canine antibodies and antibod-
ies cross-reacting with this species, which hampers detailed cytokine profiling and evaluation
of surface antigen expression. At the time the study was planned and conducted reagents neces-
sary for evaluation of most of the above mentioned markers in the dog were not available (IL-
10, TGF-β, CD69, CD71, as well as NK and Th17 cell markers) or exhibited weak cross-reactiv-
ity in commonly available assays (IL-4) [116]. Further studies in vitro and in vivo evaluating
the influence of MPA on canine lymphocytes are warranted.
In conclusion, the activity of stimulated peripheral canine lymphocytes is not only blocked
by MPA through inhibition of the proliferation of these cells in vitro, but the impact of MPA
on the development of immune tolerance induced by lymphocyte apoptosis depended on the
mechanisms of cellular activation and the concentration of MPA. Furthermore, MPA caused a
decrease in the expression of surface antigens which leads to inhibition of lymphocyte activa-
tion and function. Depending on lymphocyte activation MPA could block the expansion of tol-
erogenic Treg lymphocytes. Finally, MPA at 1 μM and 10 μM caused a significant decrease in
the function of canine lymphocytes in vitro.
Supporting Information
S1 Fig. Representative graphs demonstrating gating strategy of lymphocytes on a FSC vs.
SSC dot plot after a 72 h culture of PBMC in a 37°C, 5% CO2 environment and PHA (mito-
gen).
(TIF)
S2 Fig. Representative dot plot demonstrating gating strategy of lymphocytes positive to
Annexin V:PE and 7-AAD after a 72 h culture of PBMC in a 37°C, 5% CO2 environment
and PHA (mitogen).
(TIF)
S3 Fig. Representative dot plots demonstrating gating strategy of lymphocytes expressing (iso-
type controls and test samples) CD3 and CD4 (A), CD4 and CD8 (B), CD21 (C), CD4 and
CD25 (D), CD25 and FoxP3 (E) after a 72 h culture of PBMC in a 37°C, 5% CO2 environment
and PHA (mitogen).
(TIF)
S4 Fig. Representative histograms demonstrating gating strategy of lymphocytes expressing
PCNA (isotype control and test sample) (A), proliferating CFSE-labeled lymphocytes
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(unstimulated control and test sample) (B) after a 72 h culture of PBMC in a 37°C, 5% CO2
environment and with or without PHA (mitogen).
(TIF)
S1 Table. The percentage of lymphocytes in early (Annexin V:PE positive) and late
(Annexin V:PE and 7-AAD positive) apoptosis after 72 h culture of PBMC in a 37°C, 5%
CO2 environment with mitogens–ConA or PHA andMPA at 1 μM, 10 μM, 100 μMor with-
out MPA (solvent control– 0.1% DMSO).Mean ± SEM (n = 8) p<0.05, p<0.01 in com-
parison with control; ap<0.05 in comparison with 1 μMMPA; bp<0.05 in comparison with
10 μMMPA
(PDF)
S2 Table. The percentage and MFI of CD3+ T lymphocytes after 72 h culture of PBMC in a
37°C, 5% CO2 environment with mitogens–ConA or PHA and MPA at 1 μM, 10 μM,
100 μM or without MPA (solvent control– 0.1% DMSO).Mean ± SEM (n = 7) p<0.05,
p<0.01, p<0.001 in comparison with control; ap<0.05 in comparison with 1 μMMPA
(PDF)
S3 Table. The percentage and MFI of CD21+ T lymphocytes after 72 h culture of PBMC in
a 37°C, 5% CO2 environment with mitogens–ConA or PHA and MPA at 1 μM, 10 μM,
100 μM or without MPA (solvent control– 0.1% DMSO).Mean ± SEM (n = 7) p<0.05,
p<0.01 in comparison with control; ap<0.05, Ap<0.01 in comparison with 1 μMMPA
(PDF)
S4 Table. The percentage and MFI of CD4+ T lymphocytes after 72 h culture of PBMC in a
37°C, 5% CO2 environment with mitogens–ConA or PHA and MPA at 1 μM, 10 μM,
100 μM or without MPA (solvent control– 0.1% DMSO).Mean ± SEM (n = 7) p<0.05 in
comparison with control; ap<0.05, Ap<0.01 in comparison with 1 μMMPA
(PDF)
S5 Table. The percentage and MFI of CD8+ T lymphocytes after 72 h culture of PBMC in a
37°C, 5% CO2 environment with mitogens–ConA or PHA and MPA at 1 μM, 10 μM,
100 μM or without MPA (solvent control– 0.1% DMSO).Mean ± SEM (n = 7) p<0.05,
p<0.01, p<0.001 in comparison with control; ap<0.05, Ap<0.01 in comparison with
1 μMMPA
(PDF)
S6 Table. The CD4+/CD8+ T lymphocyte ratio after 72 h culture of PBMC in a 37°C, 5%
CO2 environment with mitogens–ConA or PHA andMPA at 1 μM, 10 μM, 100 μMor with-
out MPA (solvent control– 0.1% DMSO).Mean ± SEM (n = 7) p<0.05 in comparison with
control; ap<0.05 in comparison with 1 μMMPA
(PDF)
S7 Table. The percentage of CD4+CD8+ T lymphocytes after 72 h culture of PBMC in a
37°C, 5% CO2 environment with mitogens–ConA or PHA and MPA at 1 μM, 10 μM,
100 μM or without MPA (solvent control– 0.1% DMSO).Mean ± SEM (n = 7) p<0.05 in
comparison with control
(PDF)
S8 Table. The percentage of CD4+CD25+ T lymphocytes after 72 h culture of PBMC in a
37°C, 5% CO2 environment with mitogens–ConA or PHA and MPA at 1 μM, 10 μM,
100 μM or without MPA (solvent control– 0.1% DMSO).Mean ± SEM (n = 7) p<0.05,
The Influence of MPA on Stimulated Peripheral Canine Lymphocytes
PLOS ONE | DOI:10.1371/journal.pone.0154429 May 3, 2016 13 / 20
p<0.001 in comparison with control
(PDF)
S9 Table. The percentage of CD4+CD25+FoxP3+ T lymphocytes after 72 h culture of PBMC
in a 37°C, 5% CO2 environment with mitogens–ConA or PHA and MPA at 1 μM, 10 μM,
100 μM or without MPA (solvent control– 0.1% DMSO).Mean ± SEM (n = 7) p<0.01,
p<0.001 in comparison with control; ap<0.05 in comparison with 1 μMMPA
(PDF)
S10 Table. The MFI of FoxP3+ or CD25+ lymphocytes after 72 h culture of PBMC in a
37°C, 5% CO2 environment with mitogens–ConA or PHA and MPA at 1 μM, 10 μM,
100 μM or without MPA (solvent control– 0.1% DMSO).Mean ± SEM (n = 7) p<0.05,
p<0.01, p<0.001 in comparison with control; ap<0.05 in comparison with 1 μMMPA
(PDF)
S11 Table. The percentage and MFI of PCNA+ lymphocytes after 72 h culture of PBMC in a
37°C, 5% CO2 environment with mitogens–ConA or PHA and MPA at 1 μM, 10 μM,
100 μM or without MPA (solvent control– 0.1% DMSO).Mean ± SEM (n = 7) p<0.001
in comparison with control; Ap<0.01 in comparison with 1 μMMPA
(PDF)
S12 Table. Proliferation index of CFSE-labeled lymphocytes after 72 h culture of PBMC in
a 37°C, 5% CO2 environment with mitogens–ConA or PHA and MPA at 1 μM, 10 μM,
100 μM or without MPA (solvent control– 0.1% DMSO).Mean ± SEM (n = 8) p<0.001
in comparison with control
(PDF)
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